The National Cancer Institute (NCI) is currently looking for participants for a clinical drug trial testing the effectiveness of the cancer drug gefitinib in treating malignant mesothelioma. Gefitinib, commonly known as Iressa ®, has been used primarily to treat non-small cell lung cancer as well as breast and prostate cancer.
Gefitinib works by blocking signals within the mesothelioma cancer cells. It attaches itself to epidermal growth factor receptors (EGFR) and prevents them from activating cell division. This treatment is different from chemotherapy in that has the potential to stop the cancer cells from growing.
Possible side effects of the drug are as follows:
- Diarrhea
- Acne-like rash
- Loss of appetite
- Nausea and vomiting
- Tiredness
- Eye Problems
- Change in blood pressure
- Breathing problems
Participants in the clinical trail will receive daily doses of the drug until unacceptable toxicity levels are reached or the cancer has stopped growing. Patients will be followed for 4 years. The NCI is looking for 40 participants with malignant mesothelioma that are not candidates for surgery or radiation. To learn more about the clinical trail, please contact the National Cancer Institute.
